SPY ends the week with the most striking divergence of the past month: options traders have just pushed defensive positioning to a fresh 52-week extreme, even as the short base quietly shrinks and the borrow market remains flush with supply.
The put/call ratio is the headline. Tuesday's note described the PCR pulling back from its prior 2.55 record to 2.15, with the z-score falling to 1.38 — a meaningful de-escalation. That relief has now reversed. Tuesday's 52-week high reading of 2.55 has been overtaken: the PCR closed at 2.4783 on August 25, the new 52-week high, running 2.42 standard deviations above the 20-day mean of 1.99. The trajectory over the past two weeks is unambiguous — the ratio has climbed from 1.84 on August 10 to its current record in a nearly straight line, with only brief pauses. Put buyers have not stepped back. They have pressed harder. The ratio has now cleared every prior reading in the full 52-week dataset, which stretches back to a 52-week low of 1.27. The gap between where the PCR is now and where it spent most of the prior year is not incremental — it is a structural re-rating of hedging demand.
The lending market tells a sharply different story, and the contrast is the most important read in this note. Borrow availability is exceptionally loose — roughly 1,640% of short interest, meaning the lending pool holds more than sixteen times as many shares as are currently borrowed. The 52-week tightest point was 34.2%, so the current level represents near-peak looseness for the year. Cost to borrow is negligible at 0.29%, up only fractionally on the week despite a 15% month-on-month drift higher. Short interest itself has continued its steady retreat: 93.8 million shares, equivalent to 9.1% of the free float, down 14% over the past month. That month-long unwind is the largest sustained short covering in the dataset. The divergence is stark — options traders are buying protection at the highest rate of the year, while actual short sellers are reducing positions at their fastest clip in months. These are not the same investors expressing the same view.
Institutional flows from the most recent 13-F reporting round (as of June 30) add texture to who is moving. Jane Street added 24 million shares in the quarter — the largest addition among any top holder — while Morgan Stanley trimmed 8.1 million and Goldman Sachs cut 4.3 million. D.E. Shaw rebuilt a position of 14 million shares, adding 13.3 million in the quarter. The divergence between systematic / market-making books (Jane Street, D.E. Shaw adding) and traditional bank books (Morgan Stanley, Goldman trimming) is consistent with the broader positioning picture: hedged, active buyers are increasing gross exposure while managing net risk through the options market. That framework aligns with a record PCR alongside falling outright short interest.
Price context matters here. SPY closed at $765.91 on August 25 — up 0.32% on the day, flat over the week after recovering from Tuesday's dip. The one-month gain remains a healthy 3.7%, which makes the record options hedging all the more notable: this is not a panicked market reacting to a declining price. It is a cautious one buying protection into relative strength. The ORTEX short score of 44.7 — near the midpoint of its recent range and essentially unchanged over the past two weeks — corroborates the picture. Mechanically, the short-side setup is not stressed. The stress is in the options market, where traders are paying up for downside protection on a fund that has climbed 3.7% in a month.
What to watch heading into next week is whether the PCR holds above 2.40 or begins to fade — the prior note's peak of 2.55 on August 19 was followed by a partial unwind before the ratio pushed to a new high this week, and a similar pattern of advance-pause-advance would confirm that defensive options demand has become structural rather than episodic.
See the live data behind this article on ORTEX.
Open SPY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
